Press Releases

EndoBarrier Meta-Analysis Published in Diabetes Care Journal

BOSTON and SYDNEY – 10 May 2018 — GI Dynamics® Inc. (ASX: GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the meta-analysis, “Effects of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Type 2 Diabetic...

read more

GI Dynamics Announces Close of Second Tranche of Placement – AUD ~$1m

BOSTON and SYDNEY — 8 March 2018 — GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® is pleased to announce that it has today successfully completed the second tranche of the Placement (as detailed further in the 23 January 2018 announcement).  The closing of...

read more

GI Dynamics, Inc. Announces Results of Adjourned Special Meeting

BOSTON and SYDNEY — 28 February 2018 — GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier®, held an adjourned Special Meeting on Tuesday, 27 February 2018 at 3:00pm Eastern Standard Time (being Wednesday, 28 February 2018 at 7:00am Australian Eastern Daylight...

read more

GI Dynamics, Inc. Provides 2017 Review And 2018 Business Outlook

BOSTON and SYDNEY — 15 January 2018— GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® provides shareholders with a review of 2017 activities and its 2018 business outlook. GI Dynamics is preparing to submit an Investigational Device Exemption (IDE[1])...

read more
Page 1 of 1912345...10...Last »